In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Ophthalmology 2024 Meeting with a focus on AMD and retina.

David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration. :28

Douglas Love discusses the company’s phase 3 program in geographic atrophy. 2:37

Pravin U. Dugel, MD, discusses the next steps for the phase 3 SOL-1 and SOL-R studies. 3:54

Jeremiah Brown, MS, MD, presents results from the phase 4 Elevatum trial investigating faricimab for diabetic macular edema. 5:17

Read the full coverage here:

https://www.healio.com/news/ophthalmology/20241024/video-axitinib-shows-clinically-meaningful-treatment-burden-reduction-in-wet-amd

https://www.healio.com/news/ophthalmology/20241023/video-phase-3-geographic-atrophy-program-focuses-on-visual-acuity

https://www.healio.com/news/ophthalmology/20241021/video-ocular-therapeutix-shares-update-on-phase-3-axpaxli-studies

https://www.healio.com/news/ophthalmology/20241018/video-faricimab-shows-amazing-outcomes-in-underrepresented-patients-with-dme

Teleretinal screening for diabetic retinopathy beneficial

Source: Weng CY. The use of teleretinal screening for diabetic retinopathy. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.

Oral treatment aims to reduce GA progression by slowing vitamin A dimerization

Source: Melamud A. Gildeuretinol in geographic atrophy: Results from SAGA, a 2-year, randomized, double-masked, placebo-controlled Study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.

Fas inhibitor shows benefit in some cases of macula-off rhegmatogenous retinal detachment

Source: Borkar DS. Fas inhibition with intravitreal ONL1204 for the treatment of macula-off rhegmatogenous retinal detachment: Results from a phase 2 study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.

Disclosures: Brown reports being an investigator and speaker for Genentech and a researcher for EyeBio, Regeneron and Regenxbio. Dugel reports being executive chairman, president and CEO of Ocular Therapeutix. Eichenbaum reports being a consultant and investigator for Ocular Therapeutix. Love reports being president and CEO of Annexon Biosciences.